Items Tagged ‘olaparib’

October 31st, 2016

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

By

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress has been slow. The PARP […]

View full entry

Tags: BRCA1, BRCA2, lynparza, News, niraparib, olaparib, Ovarian Cancer, PARP inhibitor, Recurrent Ovarian Cancer, Rucaparib, Stage I Ovarian Cancer, Stage II-IV Ovarian Cancer


October 29th, 2015

Gene-Targeted Drug Can Treat Prostate Cancer

By

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib, the world’s first drug to reach the market targeted against inherited cancer mutations, was found […]

View full entry

Tags: advanced, DNA repair mutations, genomic testing, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, olaparib, Prostate Cancer, treatment-resistant


September 9th, 2015

Lynparza Improves Overall Survival in High-Risk Gastric Cancer

By

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 Americans will be diagnosed with gastric […]

View full entry

Tags: ATM, Gastric Cancer, lynparza, metastatic, News, olaparib, paclitaxel, PARP inhibitor, Stages III-IV Gastric Cancer


December 29th, 2014

Lynparza Approved in Advanced Ovarian Cancer

By

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes. According to statistics from the American Cancer Society (ACS), ovarian cancer causes more deaths than any other cancer of the female reproductive system. The ACS […]

View full entry

Tags: brca, lynparza, News, olaparib, Ovarian Cancer, parp, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


October 21st, 2014

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer

By

The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results of this study were recently reported in The Lancet Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than […]

View full entry

Tags: cedirnaib, News, olaparib, Ovarian Cancer, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer